TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. / Esparza-Baquer, Aitor; Labiano, Ibone; Sharif, Omar; Agirre-Lizaso, Aloña; Oakley, Fiona; Rodrigues, Pedro M; Zhuravleva, Ekaterina; O'Rourke, Colm J; Hijona, Elizabeth; Jimenez-Agüero, Raul; Riaño, Ioana; Landa, Ana; La Casta, Adelaida; Zaki, Marco Y W; Munoz-Garrido, Patricia; Azkargorta, Mikel; Elortza, Felix; Vogel, Andrea; Schabbauer, Gernot; Aspichueta, Patricia; Andersen, Jesper B; Knapp, Sylvia; Mann, Derek A; Bujanda, Luis; Banales, Jesus Maria; Perugorria, Maria Jesus.
In: Gut, Vol. 70, No. 7, 2020.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
AU - Esparza-Baquer, Aitor
AU - Labiano, Ibone
AU - Sharif, Omar
AU - Agirre-Lizaso, Aloña
AU - Oakley, Fiona
AU - Rodrigues, Pedro M
AU - Zhuravleva, Ekaterina
AU - O'Rourke, Colm J
AU - Hijona, Elizabeth
AU - Jimenez-Agüero, Raul
AU - Riaño, Ioana
AU - Landa, Ana
AU - La Casta, Adelaida
AU - Zaki, Marco Y W
AU - Munoz-Garrido, Patricia
AU - Azkargorta, Mikel
AU - Elortza, Felix
AU - Vogel, Andrea
AU - Schabbauer, Gernot
AU - Aspichueta, Patricia
AU - Andersen, Jesper B
AU - Knapp, Sylvia
AU - Mann, Derek A
AU - Bujanda, Luis
AU - Banales, Jesus Maria
AU - Perugorria, Maria Jesus
N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2020
Y1 - 2020
N2 - OBJECTIVE: Hepatocellular carcinoma (HCC) is a prevalent and aggressive cancer usually arising on a background of chronic liver injury involving inflammatory and hepatic regenerative processes. The triggering receptor expressed on myeloid cells 2 (TREM-2) is predominantly expressed in hepatic non-parenchymal cells and inhibits Toll-like receptor signalling, protecting the liver from various hepatotoxic injuries, yet its role in liver cancer is poorly defined. Here, we investigated the impact of TREM-2 on liver regeneration and hepatocarcinogenesis.DESIGN: TREM-2 expression was analysed in liver tissues of two independent cohorts of patients with HCC and compared with control liver samples. Experimental HCC and liver regeneration models in wild type and Trem-2-/- mice, and in vitro studies with hepatic stellate cells (HSCs) and HCC spheroids were conducted.RESULTS: TREM-2 expression was upregulated in human HCC tissue, in mouse models of liver regeneration and HCC. Trem-2-/- mice developed more liver tumours irrespective of size after diethylnitrosamine (DEN) administration, displayed exacerbated liver damage, inflammation, oxidative stress and hepatocyte proliferation. Administering an antioxidant diet blocked DEN-induced hepatocarcinogenesis in both genotypes. Similarly, Trem-2-/- animals developed more and larger tumours in fibrosis-associated HCC models. Trem-2-/- livers showed increased hepatocyte proliferation and inflammation after partial hepatectomy. Conditioned media from human HSCs overexpressing TREM-2 inhibited human HCC spheroid growth in vitro through attenuated Wnt ligand secretion.CONCLUSION: TREM-2 plays a protective role in hepatocarcinogenesis via different pleiotropic effects, suggesting that TREM-2 agonism should be investigated as it might beneficially impact HCC pathogenesis in a multifactorial manner.
AB - OBJECTIVE: Hepatocellular carcinoma (HCC) is a prevalent and aggressive cancer usually arising on a background of chronic liver injury involving inflammatory and hepatic regenerative processes. The triggering receptor expressed on myeloid cells 2 (TREM-2) is predominantly expressed in hepatic non-parenchymal cells and inhibits Toll-like receptor signalling, protecting the liver from various hepatotoxic injuries, yet its role in liver cancer is poorly defined. Here, we investigated the impact of TREM-2 on liver regeneration and hepatocarcinogenesis.DESIGN: TREM-2 expression was analysed in liver tissues of two independent cohorts of patients with HCC and compared with control liver samples. Experimental HCC and liver regeneration models in wild type and Trem-2-/- mice, and in vitro studies with hepatic stellate cells (HSCs) and HCC spheroids were conducted.RESULTS: TREM-2 expression was upregulated in human HCC tissue, in mouse models of liver regeneration and HCC. Trem-2-/- mice developed more liver tumours irrespective of size after diethylnitrosamine (DEN) administration, displayed exacerbated liver damage, inflammation, oxidative stress and hepatocyte proliferation. Administering an antioxidant diet blocked DEN-induced hepatocarcinogenesis in both genotypes. Similarly, Trem-2-/- animals developed more and larger tumours in fibrosis-associated HCC models. Trem-2-/- livers showed increased hepatocyte proliferation and inflammation after partial hepatectomy. Conditioned media from human HSCs overexpressing TREM-2 inhibited human HCC spheroid growth in vitro through attenuated Wnt ligand secretion.CONCLUSION: TREM-2 plays a protective role in hepatocarcinogenesis via different pleiotropic effects, suggesting that TREM-2 agonism should be investigated as it might beneficially impact HCC pathogenesis in a multifactorial manner.
U2 - 10.1136/gutjnl-2019-319227
DO - 10.1136/gutjnl-2019-319227
M3 - Journal article
C2 - 32907830
VL - 70
JO - Gut
JF - Gut
SN - 0017-5749
IS - 7
ER -
ID: 249423942